eISSN: 2081-2833
ISSN: 2081-0016
Medycyna Paliatywna/Palliative Medicine
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
3/2017
vol. 9
 
Share:
Share:
more
 
 
Original paper

Management of healthcare-associated infections at the end of life – a cross-sectional study

Tomasz Grądalski
,
Barbara Burczyk-Fitowska

Medycyna Paliatywna 2017; 9(3): 152–156
Online publish date: 2018/02/01
Article file
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
 

INTRODUCTION

Clinical signs of infection accompany nearly one third of advanced-disease patients [1]. The majority (53.0%) of patients on palliative care consultation receive empiric antibiotics [2]. Even after transition to comfort care, more than one third of patients may remain on antimicrobials [3]. Lack of clear hospice guidelines regarding antibiotic use may lead to a growing number of patients receiving potentially unnecessary or potentially burdensome treatment for infection [4]. Antibiotic treatment of these common diagnoses remains a challenge due to difficulties in predicting the individual therapeutic outcomes [5]. The objective of the current study summarising the institutional infection control team (ICT) activity was to determine the prevalence of healthcare-associated infections (HAI), the therapeutic strategies used, and their outcomes within hospice patients.

METHODS

The medical records of all consecutive patients (Gold Standards Framework stage C-D [6]) admitted to the hospice acute 42-bed ward in a metropolitan city of 780 thousand inhabitants between 1 September 2013 and 31 January 2016 were reviewed. Information on any potential infection risk factors was obtained from patients’ records on admission. The presence of symptoms and signs assessed to have been caused by microbial agents according to revised McGeer Criteria [7] allowed us to categorise patients into a infected patients group (IG) and a non-infected group (NIG). Episodes of infection that occurred within two days following the admission or mucosal thrush were not taken into account and excluded. Infection suspicion of unexplained origin (with fever ≥ 2 times within 12 hours) [8] in moribund patients were classified as end-of-life infection of unknown origin (EOL-IUO). The clinical outcomes within the IG were classified into: “clinical cure” (when all constitutional symptoms and signs of infection ceased), “symptomatic relief” (all symptoms disappeared but signs persisted), “symptomatic alleviation” (some symptoms disappeared or diminished), “symptomatic stabilisation”, and “worsening”. The comparison of antibiotics costs with all drugs expenses was made.
Fisher’s exact test was used to compare categorical data, the Wilcoxon rank sum test was used to compare ordinal data between the analysed groups. Kruskal-Wallis test was performed to assess the results in various types of infection. A p value of 0.05 was considered statistically significant. Institutional approval for this retrospective study was obtained.

RESULTS

Ninety per cent of 1458 admitted patients had cancer, 70.0% were totally bed-bound, and nearly half of them were hospitalized within six months before the admission (on average twice; range 1–13). The characteristics of admitted patients within the IG and NIG subgroups are presented in Table 1.
In total, 134 patients in IG (9.2%) were diagnosed with various types of HAI. They had an average of 3.51 infection risk factors (compared with 3.75 in NIG; p = 0.1). Patients with more than one infection episode per admission had an average of 4.38 (range 2–9) risk factors, compared with 3.28 (range 1–8; p = 0.0048). Patients in IG more often received antibiotics in the six months prior to the admission. The prevalence of renal insufficiency, prolonged steroid therapy, and bladder catheterisation within this group was higher (Table 2).
Thirty-two patients had more than one HAI episode (2, 3, and 4 times in 26, 5, and 1 person/s, respectively). The most common types of HAI were lower respiratory tract infection (LRTI) in 44.2% of episodes, and less prevalent were EOL-IUO and urinary tract infection (UTI; 17.4% each). In 17 cases (out of 21 diarrhoeas associated with antibiotics) Clostridium difficile (CD) aetiology was confirmed – three times as a consequence of antibiotics given at the hospice (Table 3).
A full course antibiotics was used 135 times in 117 HAIs (two drugs given in 18 cases) among which intravenous ceftriaxone applied in LRTI (30 times) or levofloxacin in UTIs (27 times) were the most common. According to physician’s preference, a single dose of gentamicin was chosen in 48 cases (23 EOL-IUOs, 12 lower respiratory tract infections and six UTIs) – sole symptomatic management was given in seven cases of EOL-IUOs. Twenty-three positive microbiology results were obtained: 14 CD toxins in faeces and nine various species in urines (Proteus mirabilis – three; Escherichia coli – two; meticillin-resistant Staphylococcus aureus (MRSA) – one, and acquired resistance to macrolides, lincosamides, and streptogramin B Staphylococcus aureus (MLS) – one; Enterococcus faecalis – one; Pseudomonas aeruginosa – one, and mixed species – one case). The pathogen-directed therapy covered 23 (13.2%) HAIs, predominantly with 14 days of oral metronidazole or vancomycin for post-antibiotic diarrhoea. Clinical improvement was seen in 121 cases (70.3%) and symptom aggravation in eight cases (4.7%) for whom the infection was fatal (Table 4).
In the full course of antibiotic therapies a significant symptomatic improvement was noted, which was more effective than the single-dose gentamicin (79.5 vs. 52.1%; p = 0.0006) or sole symptomatic management (42.9%; p = 0.045). The cost of antibiotics was 16.7% of all drug expenses (the second position behind analgesics) – for 10.2% of all admitted patients.

DISCUSSION

The ICT activity could explain the quite low (9.2% of patients) prevalence of infections observed in this study, lower than the 18.7% seen in nursing homes. It was possible through a strict sanitary regime, infection surveillance, limiting exposure (e.g. avoidance of unnecessary bladder catheterisation [9]), and monitoring asymptomatic infections, which can be found particularly in this group of patients [10]. However, other hospice studies noticed that up to 42% of terminally ill patients developed infections in the final phase of care, with one-fifth being fatal [11, 12]. The incidence rate of infections in our group (0.59% of care days) was twice as high as that observed in long-care term facilities (LCTF; 0.27% of care days), probably due to shorter length of stay [10]. In our observation infection diagnoses were associated with longer time of care, suggesting unfavourable length of stay influencing infection risk rather than an increased survival due to the use of antimicrobials. The literature gives inconsistent data in this area [13–15].
The evident number of infection risk factors within the end of life, the majority among bed-bound cancer patients, did not clearly increase this risk in IG (all admitted patients had a marked hazard of infection), as was observed in the literature [16]. It did not correspond with the increased relative risk (RR; 1.2–3.1) of pneumonias in more debilitated, with limited activity, poor nutritional status, catheterised, and tube-fed patients within LTCFs [17]. A higher mean number of risk factors within the patient subgroup of multiple infections was noted. Three modified risk factors were observed (antibiotics, prolonged steroids, and bladder catheterisation), which suggests room for prevalence improvement [18].
In our study LRTIs occurred most commonly, twice as often as UTIs, as opposed to more prevalent UTIs in some observations [12]. Antibiotic-associated diarrhoea (predominantly of CD origin) was the third leading cause, usually due to hospital antibiotics before the admission. Approximately half of those admitted came directly from hospitals, including intensive care units. In only three cases was this complication the sequence of antibiotics used at our hospice, increasing the costs of care [19, 20].
General avoidance of specimen culture testing (e.g. urine by catheterisation) was the dominant principle on the ward. A twice-daily routine of patient’s temperature monitoring was the main infection screening tool at the hospice. Approximately two thirds of the fever episodes can be due to infection, primarily of bacterial origin (usually respiratory infections due to Gram-negative bacilli) [21]. In nearly one fifth of cases within the last days of life pyrexia can be the only infection indicator. There are consistent findings indicating that treating residents for bacteriuria without symptoms is not beneficial, and possibly harmful [22]. Suspicion of bacterial diarrhoea led to the performance of toxin tests. Besides CD, multi-resistant species were revealed that can have a significant impact on advanced cancer patients and their families [23].
There are no generally accepted guidelines on antibiotic use at the end of life [24]. The antibiotic usage (8.7% of all admitted patients) was much lower than up to one third of all within the last week of life seen among patients admitted to long-term facilities or hospices [25–29]. The available studies suggest that educational interventions, including ICT activity, may reduce the number of antibiotic starts and also the days of therapy [30, 31].
Ninety per cent of infected patients in our population were treated by antimicrobials. When fever was added to the rapid (visible in terms of hours or days) multiorgan failure process, patients received a single dose of aminoglycoside. Major concerns appeared in such end-of-life situations about the risk of futility, escalating the drug toxicity, or prolonging the dying process [32]. Occasionally the watchful waiting strategy and delayed antibiotic initiation (“two-day rule”) [33] or Naproxen test (fever lysis in paraneoplastic syndrome) were tried in our hospice [34, 35]. End-of-life patients should receive antibiotics with the purpose of relieving symptoms, less commonly to eradicating infection or even to prolonging life [36]. Evident symptomatic improvement was achieved in 70.0% of all HAI cases (weakly negatively correlated with the number of risk factors), which is higher than noticed in the literature [12, 28, 36, 37]. A time-limited trial of antibiotics for some hospitalised advanced cancer patients may be reasonable because it may have comparable symptomatic effects to longer treatment. Even given once only, antimicrobials (gentamicin 160–240 mg or ceftriaxone 1–2 g) gave a substantial (40.0%) positive response rate in 15 out of 23 infected patients [38] or reduction of infective terminal respiratory secretions resistant to hyoscine [39]. This method often allowed postponement of the necessity of other symptomatic treatment usage, including antipyretics, antitussives, or analgesics.

CONCLUSIONS

Antibiotic therapy appeared to be a frequently chosen, valuable, although expensive symptom-alleviating management at the end of life. Empirical antibiotic full-course therapy improved symptoms in four fifths of HAIs; single-dose aminoglycoside was less effective and comparable with sole symptomatic management.

Authors report no conflict of interest.

REFERENCES

1. Homsi J, Walsh D, Panta R, et al. Infectious complications of advanced cancer. Support Care Cancer 2000; 8: 487-492.
2. Chun ED, Rodgers PE, Vitale CA, et al. Antimicrobial use among patients receiving palliative care consultation. Am J Hosp Palliat Care 2010; 27: 261-265.
3. Thompson AJ, Silveira MJ, Vitale CA, et al. Antimicrobial use at the end of life among hospitalized patients with advanced cancer. Am J Hosp Palliat Care 2012; 29: 599-603.
4. Yates E, Mitchell SL, Habtemariam D, et al. Interventions Associated With the Management of Suspected Infections in Advanced Dementia. J Pain Symptom Manage 2015; 50: 806-813.
5. Stosor V, Zembower TR (eds.). Infectious Complications in Cancer Patients. Cancer Treatment and Research. Springer International Publishing, Cham 2014.
6. Gold Standards Framework. Retrieved from: http://www.goldstandardsframework.org.uk/.
7. Stone ND, Ashraf MS, Calder J, et al. Surveillance Definitions of Infections in Long-Term Care Facilities: Revisiting the McGeer Criteria. Infect Control Hosp Epidemiol 2012; 33: 965-977.
8. Wójkowska-Mach J, Gryglewska B, Grodzicki T, et al. Definitions of infection in acute care hospitals and in long term care facilities. Gerontol Pol 2010; 18: 10-15.
9. Gutmanis I, Shadd J, Woolmore-Goodwin S, et al. Prevalence and indications for bladder catheterization on a palliative care unit: a prospective, observational study. Palliat Med 2014; 28: 1239-1240.
10. Wójkowska-Mach J, Gryglewska B, Czekaj J, et al. Infection control: point prevalence study versus incidence study in Polish long-term care facilities in 2009–2010 in the Małopolska Region. Infection 2013; 41: 1-8.
11. Nagy-Agren S, Haley HB. Management of infections in palliative care patients with advanced cancer. J Pain Symptom Manage 2002; 24: 64-70.
12. Vitetta L, Kenner D, Sali A. Bacterial infections in terminally ill hospice patients. J Pain Symptom Manage 2000; 20: 326-334.
13. Thai V, Lau F, Wolch G, et al. Impact of infections on the survival of hospitalized advanced cancer patients. J Pain Symptom Manage 2012; 43: 549-557.
14. White PH, Kuhlenschmidt HL, Vancura BG, et al. Antimicrobial use in patients with advanced cancer receiving hospice care. J Pain Symptom Manage 2003; 25: 438-443.
15. Mitchel BG, Ferguson JK, Anderson M, et al. Length of stay and mortality associated with healthcare-associated urinary tract infections: a multi-state model. J Hospital Infection 2016; 93: 92-99.
16. Yajima R, Ise Y, Wako T, et al. A Retrospective Study of Risk Factors for Infection in Cancer Patients Receiving Specialist Palliative Care. J Nippon Med Sch 2013; 80: 481-485.
17. Wójkowska-Mach J, Gryglewska B, Romaniszyn D, et al. Age and other risk factors of pneumonia among residents of Polish long-term care facilities. Int J Infect Dis 2013; 17: e37-e43.
18. Homsi J, Walsh D, Panta R, et al. Infectious complications of advanced cancer. Support Care Cancer 2000; 8: 487-492.
19. Yu H, Baser O, Wang L. Burden of Clostridium difficile-associated disease among patients residing in nursing homes: a population-based cohort study. Geriatrics 2016; 16: 193.
20. Thipmontree W, Kiratisin P, Manatsathit S, et al. Epidemiology of suspected Clostridium difficile-associated hospital-acquired diarrhea in hospitalized patients at Siriraj Hospital. J Med Assoc Thai 2011; 94 Suppl 1: S207-216.
21. Toussaint E, Bahel-Ball E, Vekemans M, et al. Causes of fever in cancer patients (prospective study over 477 episodes). Support Care Cancer 2006; 14: 763-769.
22. Abrutyn E, Mossey J, Berlin JA, et al. Does asymptomatic bacteriuria predict mortality and does antimicrobial treatment reduce mortality in elderly ambulatory women? Ann Intern Med 1994; 120: 827-833.
23. Schmalz O, Strapatsas T, Alefelder C, et al. Methicillin-resistant Staphylococcus aureus in palliative care: A prospective study of Methicillin-resistant Staphylococcus aureus prevalence in a hospital-based palliative care unit. Palliat Med 2016; 30: 703-706.
24. van Nordennen RT, Lavrijsen JC, Vissers KC, et al. Decision Making About Change of Medication for Comorbid Disease at the End of Life: An Integrative Review. Drugs Aging 2014; 31: 501-512.
25. Szczerbińska K. Quality of palliative care in long-term care facilities in Poland. Results from the PACE study 1. International Conference “End-of-life care for older people in long-term care facilities” 31.03-1.04.2017 Kraków.
26. Albrecht JS, McGregor JC, Fromme EK, et al. A nationwide analysis of antibiotic use in hospice care in the final week of life. J Pain Symptom Manage 2013; 46: 483-490.
27. Rosenberg JH, Albrecht JS, Fromme EK, et al. Antimicrobial Use for Symptom Management in Patients Receiving Hospice and Palliative Care: A Systematic Review. J Palliat Med 2013; 16: 1568-1574.
28. Helde-Frankling M, Bergqvist J, Bergman P, et al. Antibiotic Treatment in End-of-Life Cancer Patients – A Retrospective Observational Study at a Palliative Care Center in Sweden. Cancers 2016; 8: 84.
29. Merel SE, Meier CA, McKinney CM, et al. Antimicrobial Use in Patients on a Comfort Care Protocol: A Retrospective Cohort Study J Palliat Med. 2016; 19: 1210-1214.
30. Schwartz DN, Abiad H, DeMarais PL, et al. An educational intervention to improve antimicrobial use in a hospital-based long-term care facility. J Am Geriatr Soc 2007; 55: 1236-1242.
31. Scales K, Zimmerman S, Reed D, et al. Nurse and Medical Provider Perspectives on Antibiotic Stewardship in Nursing Homes. J Am Geriatr Soc 2016; 65: 165-171.
32. Ford PJ, Fraser TG, Davis MP, et al. Ati-infective therapy at end of life: Ethical decision-making in hospice-eligible patients. Bioethics 2005; 19: 379-392.
33. Twycross R, Wilcock A, Hoard P (eds.). Palliative Care Formulary (5th ed). Retrieved from: palliativedrugs.com.
34. Spurling GKP, DelMar CB, Dooley L, et al. Delayed antibiotics for respiratory infections. Cochrane Database Syst Rev 2013; CD004417, doi: 10.1002/14651858.CD004417.pub4.
35. Alsirafy SA, El Mesidy SM, Abou-Elela EN, et al. Naproxen test for neoplastic fever may reduce suffering. J Palliat Med 2011; 14: 665-667.
36. Reinbolt RE, Shenk AM, White PH, et al. Symptomatic treatment of infections in patients with advanced cancer receiving hospice care. J Pain Symptom Manage 2005; 30: 175-182.
37. Givens JL, Jones RN, Shaffer ML, et al. Survival and comfort after treatment of pneumonia in advanced dementia. Arch Intern Med 2010; 170: 1102-1107.
38. Clayton J, Fardell B, Hutton-Potts J, et al. Parenteral antibiotics in a palliative care unit: prospective analysis of current practice. Palliat Med 2003; 17; 44-48.
39. Spruyt O, Kausae A. Antibiotic use for infective terminal respiratory Secretions (letter). J Pain Symptom Manage 1998; 15: 263-264.
Copyright: © 2018 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.